Generation and Characterization of hiPSC-Derived Vascularized-, Perfusable Cardiac Microtissues-on-Chip

被引:0
|
作者
Arslan, Ulgu [1 ]
van den Hil, Francijna E. [1 ]
Mummery, Christine L. [1 ]
Orlova, Valeria [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Anat & Embryol, Leiden, Netherlands
来源
CURRENT PROTOCOLS | 2024年 / 4卷 / 07期
关键词
cardiac microtissues; human induced pluripotent stem cells; vascularization; vessels-on-a-chip; DISEASE; CELLS; CARDIOMYOCYTE; ORGANOIDS;
D O I
10.1002/cpz1.1097
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In the heart in vivo, vasculature forms a semi-permeable endothelial barrier for selective nutrient and (immune) cell delivery to the myocardium and removal of waste products. Crosstalk between the vasculature and the heart cells regulates homeostasis in health and disease. To model heart development and disease in vitro it is important that essential features of this crosstalk are captured. Cardiac organoid and microtissue models often integrate endothelial cells (ECs) to form microvascular networks inside the 3D structure. However, in static culture without perfusion, these networks may fail to show essential functionality. Here, we describe a protocol to generate an in vitro model of human induced pluripotent stem cell (hiPSC)-derived vascularized cardiac microtissues on a microfluidic organ-on-chip platform (VMToC) in which the blood vessels are perfusable. First, prevascularized cardiac microtissues (MT) are formed by combining hiPSC-derived cardiomyocytes, ECs, and cardiac fibroblasts in a pre-defined ratio. Next, these prevascularized MTs are integrated in the chips in a fibrin hydrogel containing additional vascular cells, which self-organize into tubular structures. The MTs become vascularized through anastomosis between the pre-existing microvasculature in the MT and the external vascular network. The VMToCs are then ready for downstream structural and functional assays and basic characterization. Using this protocol, cardiac MTs can be efficiently and robustly vascularized and perfused within 7 days. In vitro vascularized organoid and MT models have the potential to transition current 3D cardiac models to more physiologically relevant organ models that allow the role of the endothelial barrier in drug and inflammatory response to be investigated. (c) 2024 The Author(s). Current Protocols published by Wiley Periodicals LLC.Basic Protocol: Generation of VMToCSupport Protocol 1: Functional Characterization of VMToCSupport Protocol 2: Structural Characterization of VMToC
引用
收藏
页数:26
相关论文
共 50 条
  • [1] Vascularized hiPSC-derived 3D cardiac microtissue on chip
    Arslan, Ulgu
    Brescia, Marcella
    Meraviglia, Viviana
    Nahon, Dennis M.
    van Helden, Ruben W. J.
    Stein, Jeroen M.
    van den Hil, Francijna E.
    van Meer, Berend J.
    Cuenca, Marc Vila
    Mummery, Christine L.
    Orlova, Valeria V.
    STEM CELL REPORTS, 2023, 18 (07): : 1394 - 1404
  • [2] Characterization of the physiology and cardiotoxicity of cardiac 3D microtissues of hiPSC-derived cardiomyocytes (hiPSC-CMs)
    Hortigon-Vinagre, Maria P.
    Zamora, Victor
    Alageswaran, Viben
    Craig, David
    Fluri, David
    Bruton, Francis L.
    Agarkova, Irina
    Kelm, Jens M.
    Craig, Margaret A.
    Smith, Godfrey L.
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2016, 81 : 383 - 383
  • [3] Vascularized hiPSC-derived 3D cardiac microtissue on chip (vol 18, pg 1394, 2023)
    Arslan, Ulgu
    Brescia, Marcella
    Meraviglia, Viviana
    Nahon, Dennis M.
    van Helden, Ruben W. J.
    Stein, Jeroen M.
    van den Hil, Francijna E.
    van Meer, Berend J.
    Cuenca, Marc Vila
    Mummery, Christine L.
    Orlova, Valeria V.
    STEM CELL REPORTS, 2023, 18 (10): : 2003 - 2003
  • [4] Mechanical Characterization of hiPSC-Derived Cardiac Tissues for Quality Control
    Park, Seungman
    Lui, Cecillia
    Jung, Wei-Hung
    Maity, Debonil
    Ong, Chin Siang
    Bush, Joshua
    Maruthamuthu, Venkat
    Hibino, Narutoshi
    Chen, Yun
    ADVANCED BIOSYSTEMS, 2018, 2 (12)
  • [5] An isogenic hiPSC-derived BBB-on-a-chip
    Motallebnejad, Pedram
    Thomas, Andrew
    Swisher, Sarah L.
    Azarin, Samira M.
    BIOMICROFLUIDICS, 2019, 13 (06)
  • [6] Improved drug response prediction using scalable 3D hiPSC-derived cardiac microtissues
    de Korte, Tessa
    Francois, Louise
    Matsa, Elena
    Braam, Stefan R.
    Mol, Mervyn P. H.
    Christine, Mummery L.
    Davis, Richard P.
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2023, 123
  • [7] Electrophysiological characterization of hiPSC-derived cardiomyocytes
    Letang, Valerie
    Ballet, Veronique
    Redon, Nicolas
    Tariq, Fatima
    Boos, Margaux
    Illiano, Stephane
    Garry, Ambroise
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2023, 123
  • [8] Molecular and metabolomic characterization of hiPSC-derived cardiac fibroblasts transitioning to myofibroblasts
    Nagalingam, Raghu Sundaresan
    Jayousi, Farah
    Hamledari, Homa
    Dababneh, Saif
    Hosseini, Dina
    Lindsay, Chloe
    Geltink, Ramon Klein
    Lange, Philipp F.
    Dixon, Ian Michael
    Rose, Robert Alan
    Czubryt, Michael Paul
    Tibbits, Glen Findlay
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [9] Culture of hiPSC-Derived Cardiomyocytes on a Pro-Fibrotic Cardiac Extracellular Matrix Scaffold Produced by hiPSC-Derived Cardiac Fibroblasts
    Matter, Andrea
    Turner, Amy
    Aggarwal, Praful
    Olson, Benjamin
    Weihrauch, Dorothee
    Broeckel, Ulrich
    CIRCULATION, 2018, 138
  • [10] Generation of self-assembling cardiac organoids using hiPSC-derived cardiomyocytes
    Kuenzel, Karolina
    Kuenzel, Stephan R.
    Guan, Kaomei
    HELIYON, 2022, 8 (09)